To include your compound in the COVID-19 Resource Center, submit it here.

Promiliad, Spero Therapeutics, University of Connecticut deal

By WIR Staff | Jan 25, 2016 | 8:00 AM GMT

Promiliad granted Spero a worldwide, exclusive sublicense to develop and commercialize dihydrofolate

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE